Table 2

PCR-corrected parasitological and clinical outcomes among patients treated for P. falciparum malaria with dihydroartemisinin-piperaquine, grouped by year(s), month(s), and sitea

ParameterPailin, PailinVeal Veng, PursatRovieng, Preah Vihear 2009, Sep–OctVeun Sai, Ratanakiri
2008/09, Jul–Jan2009/10, Sep–Feb2010/11, Aug–Mar2008, Jul–Nov2010, Aug–Dec2009/10, Oct–Jan2010, Aug–Sep
No. of patients (%)53 (100)39 (100)29 (100)80 (100)60 (100)60 (100)57 (100)60 (100)
Day 1 positive (%)51 (100)36 (92.3)28 (96.5)78 (100)48 (81.4)42 (70.0)41 (71.9)47 (78.3)
Day 2 positive (%)34 (66.7)25 (64.1)21 (75.0)51 (65.4)17 (28.8)9 (15.0)2 (3.5)6 (10.0)
Day 3 positive (%)13 (25.5)13 (33.3)13 (44.8)6 (7.7)6 (10.2)3 (5)0 (0)0 (0)
Dropout by day 426 (11.3)2* (5.1)1 (3.5)6 (7.5)4 (6.7)0 (0)2** (3.5)1** (1.7)
LCF (%)2 (4.3)0 (0)1 (3.6)1 (1.4)6 (10.7)0 (0)0 (0)0 (0)
LPF (%)3 (6.4)3 (8.1)6 (21.4)0 (0)0 (0)0 (0)0 (0)0 (0)
ACPR (day 42) (%)42 (89.4)34 (91.9)21 (75.0)73 (98.7)50 (89.3)60 (100)55 (100)59 (100)
Cumulative risk of treatment failure (%)10.3 (4.4–22.9)7.9 (2.6–22.5)24.1 (12.3–44.1)1.3 (0.2–9.1)10.5 (4.8–21.8)0 (0–6.1)0 (0–6.1)0 (0–6.1)
  • a LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response; CI, confidence interval.

  • * , Includes one reinfection on day 35;

  • ** , includes one reinfection on day 42.